Focus on Precision Medicine AMPEL BioSolutions specializes in developing genomic and blood tests for complex diseases such as cardiovascular conditions and chronic kidney diseases, highlighting opportunities to offer advanced diagnostic and personalized therapy solutions to healthcare providers and clinics.

Innovative Technology Use Utilizing cutting-edge bioinformatics, machine learning, and RNA sequencing technologies, AMPEL presents opportunities to collaborate on or supply data analysis platforms, AI-driven diagnostics, or genomic sequencing solutions to enhance their research capabilities.

Expanding Product Portfolio With recent launches like LuGENE, NephroGene, and Cardio Gene, AMPEL demonstrates a growing pipeline that can be supplemented with complementary biotech tools, assay development services, or partnering opportunities across various diagnostic markets.

Growing Market Potential Operating in the rapidly expanding fields of genomic and molecular diagnostics within the biotechnology industry, AMPEL’s targeted disease tests position them for strategic partnerships with labs, CROs, and healthcare systems seeking innovative diagnostic solutions.

Revenue Growth and Funding With revenues estimated between $10 million and $25 million and ongoing development efforts, there are opportunities to support AMPEL’s scaling by providing technology, funding, or strategic consulting to accelerate their product commercialization and market expansion.